Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Change in Acquisitions & Divestments for 17 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Acquisitions & Divestments rose 659.65% year-over-year to $2.3 billion; the trailing twelve-month figure through Jun 2026 stood at $3.0 billion (up 171.41% YoY), and the FY2025 full-year result was $1.1 billion, up 12.6% from the prior year.
• Change in Acquisitions & Divestments improved to $2.3 billion in Q2 2026 per NBIX's latest filing, from $259.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $2.3 billion in Q2 2026 and bottomed at $71.2 million in Q3 2022.
• Historically, Change in Acquisitions & Divestments has averaged $337.1 million across 5 years, with a median of $255.0 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Change in Acquisitions & Divestments plunged 55.42% in 2022, then surged 659.65% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $162.2 million in 2022, then soared by 79.28% to $290.8 million in 2023, then declined by 13.76% to $250.8 million in 2024, then gained by 6.74% to $267.7 million in 2025, then jumped by 747.33% to $2.3 billion in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $2.3 billion, $259.2 million, and $267.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.